These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385 [TBL] [Abstract][Full Text] [Related]
11. Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. Wen C; Bi YL; Hu H; Huang SY; Ma YH; Hu HY; Tan L; Yu JT J Alzheimers Dis; 2022; 85(3):1143-1151. PubMed ID: 34924386 [TBL] [Abstract][Full Text] [Related]
12. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus. Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890 [TBL] [Abstract][Full Text] [Related]
13. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875 [TBL] [Abstract][Full Text] [Related]
14. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097 [TBL] [Abstract][Full Text] [Related]
15. The Memory Alteration Test Is Correlated with Clinical, Cerebrospinal Fluid, and Brain Imaging Markers of Alzheimer Disease in Lima, Peru. Custodio N; Malaga M; Montesinos R; Chambergo-Michilot D; Baca F; Carbajal JC; Huilca JC; Herrera-Perez E; Lira D; Diaz MM; Lanata S Dement Geriatr Cogn Disord; 2023; 52(5-6):309-317. PubMed ID: 37827146 [TBL] [Abstract][Full Text] [Related]
16. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment. Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986 [TBL] [Abstract][Full Text] [Related]
17. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum. Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease. Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT; J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067 [TBL] [Abstract][Full Text] [Related]
19. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease. García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810 [TBL] [Abstract][Full Text] [Related]
20. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]